| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
WANG XX, CUI HF. The development of new drug targeting hepcidin[J]. Chin Pharmacol J, 2018, 53(6): 405-410. DOI: 10.11669/cpj.2018.06.001. |
| [5] |
|
| [6] |
PIETRANGELO A. Ferroportin disease: Pathogenesis, diagnosis and treatment[J]. Haematologica, 2017, 102(12): 1972-1984. DOI: 10.3324/haematol.2017.170720. |
| [7] |
ZOLLER H, KOCH RO, THEURL I, et al. Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload[J]. Gastroenterology, 2001, 120(6): 1412-1419. DOI: 10.1053/gast.2001.24033. |
| [8] |
MAYR R, JANECKE AR, SCHRANZ M, et al. Ferroportin disease: A systematic meta-analysis of clinical and molecular findings[J]. J Hepatol, 2010, 53(5): 941-949. DOI: 10.1016/j.jhep.2010.05.016. |
| [9] |
ZHANG W, LV T, HUANG J, et al. Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene: A case report and a review of the literature[J]. Medicine (Baltimore), 2017, 96(38): e8064. DOI: 10.1097/MD.0000000000008064. |
| [10] |
ALTAMURA S, KESSLER R, GR?NE HJ, et al. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload[J]. Cell Metab, 2014, 20(2): 359-367. DOI: 10.1016/j.cmet.2014.07.007. |
| [11] |
CHEN SR, YANG LQ, CHONG YT, et al. Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4[J]. Intern Med J, 2015, 45(6): 672-676. DOI: 10.1111/imj.12764. |
DownLoad:
